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Background: In Phase I evaluation of CT-2103 (paclitaxel poliglumex), prolongation of 
prothrombin time (PT) and activated thromboplastin time (aPTT) was observed, without clinical 
consequence, with doses 1.3–1.5 times higher than the current clinical dose of 175 mg/m2. This 
Phase I, open-label, nonrandomized pilot study was performed to study the effect of the standard 
dose regimen on blood coagulation.
Methods: Seven previously treated solid tumor patients received CT-2103 175 mg/m2 
intravenously on day 1 of 21-day cycles for a mean of 5.4 cycles (median 4, range 2–14). 
Plasma samples were collected for cycle 1 predose and at hours 1, 24, 48, and 72 after the end 
of administration for drug levels, and for PT and aPTT assays.
Results: No coagulopathy-related adverse events were documented. Bleeding time remained 
normal in the six patients tested, with transient increases in PT and aPTT noted but resolving 
within 72 hours. Titration studies at 100 µg/mL of CT-2103 (corresponding to the standard 
clinical dose) prolonged PT and aPTT clotting times, produced a modest dose-dependent 
reduction of thrombin and factor Xa, and no significant changes in factors IXa, XIa, or XIIa. 
Two patients achieved stable disease for $10 cycles.
Conclusion: CT-2103 is associated with transient prolongation of PT and aPTT without 
clinical sequelae.
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Introduction
CT-2103 (paclitaxel poliglumex), the ester conjugate of α-poly-L-glutamic acid and 
paclitaxel linked through a 2′ hydroxyl site,1–3 is an investigational agent under develop-
ment for the treatment of human cancer.4–10 The bioactive moiety, paclitaxel, is released 
from the polymeric backbone primarily in tumor tissue after uptake and proteolytic 
hydrolytic degradation of the compound. CT-2103 shares structural similarities (ie, a 
large polyanionic molecule) with heparin.
In an initial Phase I clinical trial, prolongation of prothrombin time (PT) and 
activated partial thromboplastin time (aPTT) was observed in patients given doses 
1.3–1.5 times higher than the current clinical dose of 175 mg/m2.11 This effect was 
dose-dependent, and PT and aPTT clotting times returned to baseline within 48 hours. 
The time frame was consistent with the mean peak plasma drug concentration (Cmax) 
during the first 48 hours. However, bleeding complications were not seen in patients 
receiving CT-2103. The correlation, if any, between CT-2103 administration and 
prolongation of PT and aPTT clotting times was therefore unclear.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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The procoagulant inhibitory effect of CT-2103 in human 
blood12,13 was subsequently studied in ex vivo and in vitro stud-
ies, using a dose range based on the plasma Cmax in patients 
who had received CT-2103 at doses up to 225 mg/m2. These 
Phase 1 studies confirmed a dose-dependent prolongation of 
PT and aPTT values, but did not show a significant inhibi-
tion of these effects with the addition of protamine sulfate or 
epichlorohydrin triethanolamine cellulose, two agents known 
to inhibit the “heparin-like” effect of the assays. Addition of 
normal plasma partially corrected the prolonged PT and aPTT 
values, suggesting an inhibitor effect, and a reduction in aPTT 
times was not observed upon addition of platelet phospho-
lipids and hexagonal phase phospholipids, arguing against a 
“lupus anticoagulant” effect. The current pilot study therefore 
sought to investigate the mechanism for prolonged PT and 
aPTT times further in patients treated with CT-2103.
Materials and methods
study objectives
The purpose of the study was to determine whether standard-
dose single-agent CT-2103 affected blood coagulability when 
administered to patients with solid tumors. Specific study 
objectives were: to determine the effect of CT-2103 over a 
range of therapeutically relevant concentrations on PT and 
aPTT measurements in ex vivo coagulation with normal 
human blood; to examine the effect of replacing heparin 
with therapeutically relevant concentrations of CT-2103 
in in vitro assays of heparin/antithrombin III (AT-III) inhibi-
tion of thrombin and factor Xa enzyme activity; and to assess 
the effect of CT-2103 on in vitro enzyme activity assays of 
thrombin and factors Xa, IXa, XIa, and XIIa.
Design
This was an open-label, nonrandomized, single-center Phase I 
study of CT-2103 175 mg/m2 given intravenously (IV) on day 
1 of 21-day cycles in patients with advanced solid tumors. 
Patients were treated until unacceptable toxicity, disease 
progression, or a complete response occurred, and patients 
demonstrating a complete response were permitted to receive 
a maximum of two additional cycles of study medication.
Eligible patients were those who had either failed 
first-line therapy or had a tumor for which no first-line 
therapy was available and were felt to be appropriate for 
treatment with a single-agent taxane. Additional eligibility 
requirements were aged 18–80 years, Eastern Cooperative 
Oncology Group performance status 0 or 1, adequate hema-
tologic function (hemoglobin $9 g/dL, absolute neutrophil 
count $1.2 × 109/L, platelet count $100 × 109/L), adequate 
renal function with serum creatinine ,1.25 × upper limit of 
normal range [ULN], and adequate hepatic function [total 
bilirubin #1.25 × ULN and aspartate transaminase, alanine 
transaminase, and alkaline phosphatase #2.5 × ULN]). 
If liver metastases were present, aspartate transaminase 
and alanine transaminase had to be #5 × ULN, and higher 
alkaline phosphatase levels were permitted with laboratory 
documentation demonstrating bone origin (ie, bone metasta-
ses). Women of reproductive potential were required to have 
a negative pregnancy test prior to study entry, and all patients 
had to sign an institutional review board-approved informed 
consent form indicating they were aware of the investigational 
nature and known risks of the study.
Exclusion criteria included patient or family history of 
hemorrhagic diathesis, recent history of thrombosis or prior 
coagulopathy, and peripheral neuropathy .Grade 1. Patients 
could not be on anticoagulant or antiplatelet adhesive therapy, 
including anticoagulants for venous access maintenance, and 
prior treatment for cancer was prohibited within three weeks 
of the first study treatment.
Laboratory and clinical evaluations (eg, physical exami-
nation, Eastern Cooperative Oncology Group performance 
status) were done at baseline, during treatment, and at 
the end of treatment visits. Tumor response was assessed 
in the third week of every even-numbered treatment cycle. 
Toxicities were assessed according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events, 
Version 3, at each patient visit.
Blood samples to evaluate plasma drug levels and 
coagulation parameters were collected into Vacutainer 
tubes containing sodium heparin during cycle 1 at predose 
and again at hours 1, 24, 48, and 72 after the end of the first 
CT-2103 administration. Blood samples were collected 
from the arm contralateral to the site used for the CT-2103 
infusion. After collection, the blood samples were placed in 
an ice bath and then centrifuged at 2000 rpm for 15 minutes at 
4°C to separate plasma. Plasma was transferred into polypro-
pylene screwcap vials and stored in a freezer set to maintain 
a temperature of −60°C to 70°C until analysis.
If PT and/or aPTT levels were elevated at the 72-hour 
evaluation, additional PT and aPTT assessments were done 
every 3–5 days until levels returned to normal.
Drug reconstitution and dilution
Before administration, CT-2103 was reconstituted to a solu-
tion at a strength of 90 mg/10 mL by rapidly injecting 9.8 mL International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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sterile water for injection into the vial. The required volume 
of reconstituted drug product (to produce the required dose 
per square meter of body surface area) was transferred to a 
low-adsorption non-PVC plastic IV bag containing 100 mL of 
5% dextrose injection in water (D5W). A volume of diluent 
equivalent to the volume of reconstituted drug solution was 
not withdrawn from the IV bag; the entire volume of 100 mL 
D5W was used. The diluted drug product was administered 
with a pump as a 10-minute infusion into a peripheral vein or 
central line using a low-adsorption non-PVC administration 
set, without an inline filter.
Bleeding and coagulation assays
The CT-2103 concentrations used in these in vitro and ex vivo 
coagulation studies were determined from human clinical 
pharmacokinetic data obtained in four prior Phase I dose-
escalation studies with one-, two-, and three-week schedules 
(Table 1). Results revealed a biphasic decline in CT-2103 
concentration, with a distribution phase of approximately 
48 hours followed by a longer terminal phase associated 
with drug elimination. Bleeding time was performed by the 
traditional Ivy method.14
PT and aPTT assays
A series of samples containing 898 µL pooled normal plasma 
(Haematologic Technologies, Inc., Essex Junction, VT) and 
102 µL of CT-2103 in 50 mM Tris, 0.175 M NaCl, 7.5 mM 
EDTA pH 8.4 (assay buffer) yielding 0, 50, 100, 150, 200, 
250 or 300 µg paclitaxel equivalents/mL were prepared in 
microcentrifuge tubes. The tubes were mixed by inversion 
and placed on ice. Next, 100 µL of each sample was added to 
each well of an MLA Electra 700 coagulation timer cuvette, 
and the aPTT and PT assays were initiated on an MLA 
Electra 700 coagulation timer which dispensed 200 µL per 
well of PT reagent (Hemoliance RecombiPlasTin; Instrument 
Laboratories, Lexington, MA) for the PT test or 100 µL per 
well of Auto aPTT (BioMerieux, Durham, NC) and 100 µL 
per well 25 mM CaCl2 (JT Baker, Phillipsburg, NJ) with a 
300-second incubation time for the aPTT assay. Data were 
represented in a plot of µg paclitaxel-equivalents/mL versus 
PT and aPTT clot times in seconds.
heparin/AT-III assays for inhibition  
of α-thrombin and factor Xa
A series of heparin standards was prepared by adding 0–1.0 U/
mL heparin sodium (Porcine Elkin-Sinn, Inc., Cherry Hill, 
NJ) to microcentrifuge tubes and diluting up to final volumes 
of 900 µL with 50 mM Tris, 0.175 M NaCl, 7.5 mM EDTA 
pH 8.4 (assay buffer). A series of CT-2103 dilutions was 
prepared by adding various quantities to a microcentrifuge 
tube and diluting up to 900 µL with assay buffer, then 100 µL 
of a 350 µg/mL solution of human AT-III (Haematologic 
Technologies, Inc.) was added to the heparin-standard and 
CT-2103 tubes. A negative control was also included by add-
ing only the 300 µg paclitaxel-equivalents/mL volume to a 
microcentrifuge tube, bringing the volume up to 1000 µL with 
assay buffer (no AT-III). All tubes were mixed by inversion. 
Next, 100 µL of each sample or standard was transferred 
to a medium binding plate (CoStar, Bethseda, MD) and 
the plate incubated at 37°C for four minutes. Following 
incubation, 50 µL/well of 6 NIH U/mL human α-thrombin 
or 50 µL/well of 12 U/mL human factor Xa (Haematologic 
Technologies, Inc.) was added for the respective tests, and 
the plate incubated again at 37°C for exactly 30 seconds. 
Next, 100 µL of 1 mM Spectrozyme TH or Spectrozyme Xa 
(American Diagnostica, Stamford, CT) was added to each 
well of the plate and beginning immediately, the change in 
absorbance (∆A405/min) was monitored for five minutes in 
a Versa Max plate spectrophotometer (Molecular Devices, 
Sunnyvale, CA). A standard curve was generated by plotting 
the heparin concentration (units/mL; abscissa) versus the 
∆A405/min (ordinate). CT-2103 inhibition was expressed in 
terms of heparin units per milligram of CT-2103.
Factor IXa inhibition assay
First, 220 µL of 15 µM human factor IXa in 50 mM Tris, 
100 mM NaCl pH 7.4 plus 33% (v/v) ethylene glycol with 
and without 100 µg paclitaxel-equivalents/mL was added 
to selected wells of a medium binding assay plate (CoStar). 
After a brief incubation, 25 µL of 10 mM Spectrozyme 
Table 1 Time to peak plasma concentration of conjugated taxane 
with various cT-2103 doses
Study  
number
n  Dose (mg/m2) Cmax (μg/mL), mean   
and SD
1052a 6 233 117.7 ± 21.2
6 266 173.0 ± 79.2
1052b 6 177   77.5 ± 24.4
3 210 105.1 ± 8.6
101 2 235   98.7 ± 17.5
3 270 146.0 ± 17.3
102 5 20   11.6 ± 2.5
4 40   18.1 ± 1.3
105 6 235 131.0 ± 45.9
6 270 158.2 ± 25.6
Abbreviations: sD, standard deviation; cmax, time to peak plasma concentration.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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IXa (American Diagnostica) was added and, beginning 
immediately, ∆A405/min was monitored for five minutes 
in a Versa Max plate spectrophotometer. Results were 
expected to be quantitative, indicating whether the addition 
of CT-2103 caused direct inhibition of factor IXa.
Factor XIa and factor XIIa  
inhibition assays
One hundred microliters of 1.0 µg/mL human factor XIa 
(Hematologic Technologies) with or without 100 µg pacli-
taxel equivalents/mL in assay buffer was added to selected 
wells of a medium binding assay plate (CoStar). Following 
incubation at 37°C for four minutes, 100 µL of 400 µM 
Spectrozyme XIa (Chromogenix, Milano, Italy) or 100 µL 
of 200 µM Spectrozyme XIIa (American Diagnostica) was 
added as appropriate for the respective tests, and beginning 
immediately ∆A405/min was monitored for five minutes in a 
Versa Max plate spectrophotometer. Results were expected to 
be quantitative, indicating whether the addition of CT-2103 
caused direct inhibition of factor XIa or factor XIIa.
Results
Seven patients were enrolled in the study from February 2002 
through to December 2003. As shown in Table 2, patients 
had been heavily pretreated prior to study enrollment. All 
but one patient had undergone surgical resection, and three 
of seven had received radiation therapy.
All patients experienced at least one adverse event, but 
most adverse events were #Grade 2. Grade 3/4 adverse 
events included one instance each of leukopenia (Grade 3), 
neutropenia (Grade 4), and gamma-glutamyl transpeptidase 
increase (Grade 3). The only serious adverse event was a 
Grade 2 occurrence of intestinal obstruction in a patient with 
primary peritoneal cancer, but this was not considered related 
to the study medication.
The mean number of cycles delivered was 5.4 (median 4, 
range 2–14). At the first efficacy assessment after cycle 2, 
three patients were found to have progressive disease and dis-
continued study treatment. Two of the four remaining patients 
had progression by cycle 4, and two patients continued with 
stable disease through cycle 10. One patient ended the study 
with stable disease at cycle 10, and one patient maintained 
stable disease for over a year until progression was found 
on the post-cycle 14 assessment.
Bleeding time was evaluated pre- and post-CT-2103 
administration in six subjects and remained within normal 
limits, with only minimal intrapatient variation.
A linear regression analysis of CT-2103 in the Phase I 
dose-escalation studies versus the experimentally deter-
mined Cmax values showed that the highest concentration 
of CT-2103 utilized (300 µg/mL) was approximately 
1.5–2.0 × the Cmax observed at the highest patient dose 
administered.11
PT and aPTT assays
As described in the methods section, CT-2103 was titrated 
into pooled normal plasma, with final concentrations rang-
ing from 50 to 300 µg/mL; each sample was approximately 
one part CT-2103 to nine parts plasma. One part of this mix 
was added to two parts of RecombiPlasTin to initiate the 
PT and one part Auto aPTT plus one part CaCl2 to initiate 
the aPTT assay. CT-2103 titration resulted in PT clot times 
ranging from 18.2 to 91.3 seconds and aPTT clot times of 
104.1 to .311 seconds, which was the maximum detection 
level of the instrument (Figure 1). Comparison of the blank 
to buffer (0) control times of both PT and aPTT indicated 
a slight prolongation in the clot times with the addition of 
assay buffer only in a ratio of 1:10 in plasma.
The 100 µg/mL CT-2103 concentration (corresponding to 
the typical clinical dose) resulted in a 1.9× prolongation of the 
PT clot time and a 6.8× prolongation of the aPTT clot time, 
the maximum that could be measured with the instrument. At 
the maximal concentration of CT-2103, the PT clot time was 
prolonged 6.5×. Actual patient aPTT values chronologically 
Table 2 Baseline patient characteristics
Age mean 62.9
median (range)  64 (51–77)
Gender, n (%) male 1 (14%)
female 6 (86%)
Baseline ecOG Ps – n (%) 0 2 (29%)
1 5 (71%)
Months since diagnosis mean 51.3
median (range)  49.6 (14–97)
Disease stage, n (%) IIIc 1 (14%)
IV 6 (86%)
Tumor types ovarian 3 (43%)
NscLc 1 (14%)
primary peritoneal 1 (14%)
small cell lung 1 (14%)
endometrial 1 (14%)
Prior treatment regimens 3 1 (14%)
4 1 (14%)
5 4 (57%)
9 1 (14%)
Abbreviations: NscLc, nonsmall cell lung cancer; ecOG, eastern cooperative 
Oncology Group.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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after treatment are shown in Figure 2. A transient increase 
is shown.
heparin/AT-III assays for inhibition  
of thrombin and factor Xa enzyme activity
A standardized heparin preparation was titrated into the assay 
to achieve final concentrations ranging from 0.125 to 1.0 U/
mL, and the inhibition of thrombin and factor Xa enzyme 
activity by the resulting heparin/AT-III complex were mea-
sured using a chromogenic substrate (Figure 3). These data 
demonstrated a typical dose-response curve of heparin/AT-III 
complex inhibition of both thrombin and factor Xa activity.
CT-2103 was then titrated into the assay system in place 
of heparin at a range of final concentrations. Increasing 
concentrations of CT-2103 in the assay system resulted in a 
dose-dependent reduction of thrombin (Table 3) and factor Xa 
(Table 4) enzyme activity, expressed as heparin-equivalents 
U/mL, from 0.19 to 0.35 U/mL of heparin.
Table 5 displays control experiments performed with 
AT-III omitted from the assay, showing that the observed 
inhibition was independent of AT-III. Collectively, these 
data indicate that CT-2103 does not express heparin-like 
activity and confirm that CT-2103 interferes with the ability 
of thrombin and factor Xa to hydrolyze the chromogenic 
substrates, Spectrozyme-TH and Spectrozyme-Xa.
Factor IXa, XIa and XIIa  
enzyme inhibition assays
To investigate the sharp increase in aPTT clot time further, 
100 µg of CT-2103 was added to chromogenic assays for 
factors IXa, Xia, and XIIa. These assays (Table 6) showed 
only a slight decrease in ∆A405/min for factor XIIa and a much 
greater increase for factor XIa.
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Table 3 cT-2103 inhibition of α-thrombin activity in heparin assay
CT-2103 
dose (μg/mL)
Change in 
A405/min
Heparin 
equivalent (U/mL)
Heparin 
(U/mg)
0 245 0.04 – 
50 150 0.19 3.8
100 141 0.21 2.1
150 122 0.26 1.8
200 116 0.28 1.4
250 102 0.33 1.3
300 95.3 0.35 1.2
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Figure 3 Dose-response curve of heparin/antithrombin III complex inhibition of 
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opposed to some form of chemical “interference”. However 
this “interference” did not appear to have a dramatic effect 
on assays conducted in this study using purified proteins and 
synthetic substrates. Furthermore, these studies demonstrate 
that the mechanism does not involve interference with the 
protein/phospholipid membrane interaction.
Because CT-2103 affects aPTT clotting times, it is 
conceivable that the mechanism relates to inhibition of the 
prothrombinase complex (central to both the intrinsic and 
extrinsic pathways) or to one of the important feedback path-
ways essential for the propagation phase of blood coagulation. 
It is important to note that the assays conducted in this study 
focused on inhibition of procoagulant enzymes, as determined 
by their ability to hydrolyze small synthetic substrates, and 
any effect CT-2103 may have on the conversion of zymogens 
to their respective enzymes remains to be investigated.
Conclusion
It is proposed that the mechanism of inhibitory activity relates 
to inhibition of the prothrombinase complex or one of the 
feedback pathways. CT-2103 presents a new clinical laboratory 
abnormality for at least 48 hours following dosing which has no 
observable clinical significance. However, some free paclitaxel 
(,5% of the paclitaxel dose) undergoes hepatic clearance and 
inhibits hepatic cytochrome P450. Patients receiving warfarin 
before or during CT-2103 administration should have con-
tinuous monitoring of their international normalized ratio and 
appropriate and careful modulation of their warfarin dosage.
Disclosure
FO and JS are employees of Cell Therapeutics, Inc., but 
final interpretation of the results of this study was made by 
individuals not employed by Cell Therapeutics, Inc.
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